Reed Seward: AI and the Future of Clinical Trial Site Selection

The clinical research industry continues to search for faster and more effective ways to bring new treatments to market. One area receiving significant attention is clinical trial site selection. As Reed Seward defines it, choosing the right sites can determine whether a study meets its enrollment goals, stays within budget, and finishes on schedule. In the past, sponsors relied heavily on manual assessments, historical performance, and personal networks to identify suitable research locations While these methods offered value, they often lacked the speed and precision needed for modern studies. Artificial intelligence is now changing this process by helping sponsors make smarter decisions based on large volumes of real-world data

AI can evaluate information from multiple sources simultaneously. These sources may include electronic health records, insurance claims, population health data, previous trial results, and site performance metrics By analyzing these datasets, AI can identify patterns that would be difficult for humans to detect manually. This capability allows sponsors to pinpoint sites with strong recruitment potential, experienced investigators, and access to the right patient populations.

One of the biggest advantages of AI is its ability to improve enrollment planning Patient recruitment remains one of the leading causes of trial delays. AI-powered tools can estimate the

number of eligible participants in a specific region and predict how quickly a site can enroll them. With better forecasting, sponsors can focus their efforts on locations that are more likely to meet recruitment targets and contribute to study success

AI also helps reduce operational risk. Some research sites may appear qualified on paper but struggle with staffing shortages, slow startup processes, or limited patient access Advanced algorithms can evaluate past performance and identify warning signs before a site is selected. As a result, sponsors can avoid costly mistakes and build stronger study networks from the beginning

Another important benefit involves improving diversity in clinical research Many studies have historically struggled to include participants from a wide range of backgrounds AI can analyze demographic and healthcare access data to identify underserved communities and potential research locations that may help increase representation More diverse participation leads to findings that better reflect real-world populations and treatment outcomes.

The future of site selection will likely combine AI technology with human expertise While algorithms can process data quickly and uncover valuable insights, experienced clinical professionals provide context that technology alone cannot offer They understand local healthcare environments, regulatory requirements, and investigator relationships that influence site performance.